Isofol reaches 440 patients in global Phase III AGENT study
GOTHENBURG, Sweden, December 9, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that 440 patients has been successfully recruited in the global Phase III AGENT study for the treatment for advanced colorectal cancer.Isofol's drug candidate, arfolitixorin, is evaluated for treatment of patients with first-line metastatic colorectal cancer (mCRC). The AGENT study is currently being conducted in the U.S., Canada, Europe, Australia and Japan at more than 90 clinics. The primary endpoint of the AGENT study is overall response rate (ORR).